Qiagen NV (Qiagen NV) FCF Margin %

: 19.47% (As of Dec. 2023)

View and export this data going back to 1996. Start your Free Trial

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Qiagen NV's Free Cash Flow for the three months ended in Dec. 2023 was $99 Mil. Qiagen NV's Revenue for the three months ended in Dec. 2023 was $509 Mil. Therefore, Qiagen NV's FCF Margin % for the quarter that ended in Dec. 2023 was 19.47%.

As of today, Qiagen NV's current FCF Yield % is 3.37%.

The historical rank and industry rank for Qiagen NV's FCF Margin % or its related term are showing as below:

QGEN' s FCF Margin % Range Over the Past 10 Years
Min: 3.67 Med: 14.65 Max: 26.43
Current: 15.09

During the past 13 years, the highest FCF Margin % of Qiagen NV was 26.43%. The lowest was 3.67%. And the median was 14.65%.

QGEN's FCF Margin % is ranked better than
84.82% of 224 companies
in the Medical Diagnostics & Research industry
Industry Median: -10.51 vs QGEN: 15.09

Qiagen NV FCF Margin % Historical Data

The historical data trend for Qiagen NV's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Qiagen NV Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

3.67

8.21

19.21

26.43

15.09

Qiagen NV Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %																15.61	6.91	16.24	17.58	19.47

Competitive Comparison

For the Diagnostics & Research subindustry, Qiagen NV's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Qiagen NV FCF Margin % Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Qiagen NV's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Qiagen NV's FCF Margin % falls into.

Qiagen NV FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Qiagen NV's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	296.653	/	1965.311
	=	15.09 %

Qiagen NV's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	99.146	/	509.162
	=	19.47 %

Qiagen NV FCF Margin % Related Terms

Thank you for viewing the detailed overview of Qiagen NV's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Qiagen NV (Qiagen NV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Qiagen NV (NYSE:QGEN) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

1QGEN:Italy QIAd:UK 0RLT:UK QIA:Germany QIA:Germany QIA:Germany QIA:Germany QGEN:Austria

Address

Hulsterweg 82, Venlo, LI, NLD, 5912 PL

Website

https://www.qiagen.com

Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (over 45% of 2022 sales), followed by EMEA (nearly 35%), and Asia-Pacific (nearly 20%).

Executives